# BioCryst Reports FDA Approval of Orladeyo Pellets for Ages 12 and Older

The October 21 announcement expands formulation options for preventing hereditary angioedema attacks.

By Will Langan | 24X7 News
Published: 2026-10-27T09:03:11.344Z
Updated: 2026-10-27T09:03:11.344Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/biocryst-orladeyo-pellets-adult-adolescent-approval-2026

Launch Catch-Up — Approval Announced October 21, 2026

BioCryst said the FDA approved a 150-milligram oral-pellet formulation of Orladeyo for preventing hereditary angioedema attacks in adults and adolescents aged 12 and older.

The October 21 announcement describes an additional formulation of berotralstat, rather than a newly discovered medicine. Orladeyo capsules were approved for patients 12 and older in December 2020, and pellets for children aged 2 to under 12 were approved in December 2025, according to the company.

The new formulation offers an alternative for patients who have difficulty swallowing capsules or prefer pellets. BioCryst said the supplemental application included manufacturing information and data comparing pellet safety and tolerability with capsules.

Orladeyo is intended for prevention, not treatment of an acute attack. Its safety information includes gastrointestinal side effects and drug-interaction risks. The announcement does not establish that the medicine is appropriate for every patient or that an individual’s insurance will cover it.

Sources:
BioCryst announcement, October 21: https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-us-fda-approval-orladeyor-150-mg-oral-pellets

## Sources
- BioCryst: October 21 approval announcement: https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-us-fda-approval-orladeyor-150-mg-oral-pellets